Advertisement

Cancer Causes & Control

, Volume 23, Issue 9, pp 1557–1565 | Cite as

Serum 25-hydroxyvitamin D, vitamin A, and lung cancer mortality in the US population: a potential nutrient–nutrient interaction

  • Ting-Yuan David ChengEmail author
  • Marian L. Neuhouser
Original paper

Abstract

Objective

Excess vitamin A may interrupt vitamin D-mediated transcription of target genes. This study investigated whether serum 25-hydroxyvitamin D [25(OH)D] concentrations were associated with lung cancer mortality, and whether this association varied by excess circulating vitamin A and vitamin A/β-carotene supplement use.

Method

We analyzed 16,693 men and women in the Third National Health and Nutrition Examination Survey (NHANES III), 1988–1994. Lung cancer mortality (n = 258, 104 were former smokers and 23 were never smokers) were identified through National Death Index as of 2006. Serum 25(OH)D was measured by a radioimmunoassay. Vitamin A biomarkers including serum retinol, β-carotene, and retinyl esters were measured by HPLC. Supplement use for the past month was obtained by self-report. Multivariate-adjusted hazard ratios (HR) were estimated by Cox proportional hazard models.

Results

There was no association of serum 25(OH)D with overall lung cancer mortality. Among nonsmokers, ≥44 vs. <44 nmol/L of serum 25(OH)D was associated with a decreased risk (HR = 0.53, 95 % CI = 0.31–0.92, former/never smokers and HR = 0.31, 95 % CI = 0.13–0.77, distant-former [quit ≥20 years]/never smokers). The associations were not observed among participants with excess circulating vitamin A (serum retinyl esters ≥7.0 μg/dL or the ratio of retinyl esters to retinol ≥0.08) or vitamin A/β-carotene supplement users. However, statistical evidence to support effect modification of vitamin A was less clear.

Conclusions

Serum 25(OH)D concentrations were inversely associated with lung cancer mortality in nonsmokers. The beneficial association was diminished among those with excess circulating vitamin A or vitamin A/β-carotene supplement users.

Keywords

Serum 25-hydroxyvitamin D Retinol Retinyl esters Lung cancer The Third National Health and Nutrition Examination Survey (NHANES III) 

Notes

Acknowledgments

Funding for this work was provided by the Fred Hutchinson Cancer Research Center, Seattle, WA.

Conflict of interest

The authors declare that they have no conflict of interest.

Supplementary material

10552_2012_33_MOESM1_ESM.doc (37 kb)
Supplementary material 1 (DOC 37 kb)

References

  1. 1.
    Samet JM, Avila-Tang E, Boffetta P et al (2009) Lung cancer in never smokers: clinical epidemiology and environmental risk factors. Clin Cancer Res 15:5626–5645PubMedCrossRefGoogle Scholar
  2. 2.
    Deeb KK, Trump DL, Johnson CS (2007) Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nat Rev Cancer 7:684–700PubMedCrossRefGoogle Scholar
  3. 3.
    Hansdottir S, Monick MM, Hinde SL, Lovan N, Look DC, Hunninghake GW (2008) Respiratory epithelial cells convert inactive vitamin D to its active form: potential effects on host defense. J Immunol 181:7090–7099 Baltimore, Md.: 1950PubMedGoogle Scholar
  4. 4.
    Menezes RJ, Cheney RT, Husain A et al (2008) Vitamin D receptor expression in normal, premalignant, and malignant human lung tissue. Cancer Epidemiol Biomarkers Prev 17:1104–1110PubMedCrossRefGoogle Scholar
  5. 5.
    Turner A, McGowan L, Millen A, et al. (2012) Circulating DBP level and prognosis in operated lung cancer: an exploration of pathophysiology. Eur Respir J. doi: 10.1183/09031936.00002912
  6. 6.
    Parise RA, Egorin MJ, Kanterewicz B et al (2006) CYP24, the enzyme that catabolizes the antiproliferative agent vitamin D, is increased in lung cancer. Int J Cancer 119:1819–1828PubMedCrossRefGoogle Scholar
  7. 7.
    Kim B, Lee HJ, Choi HY et al (2007) Clinical validity of the lung cancer biomarkers identified by bioinformatics analysis of public expression data. Cancer Res 67:7431–7438PubMedCrossRefGoogle Scholar
  8. 8.
    Chen G, Kim SH, King AN et al (2011) CYP24A1 is an independent prognostic marker of survival in patients with lung adenocarcinoma. Clin Cancer Res 17:817–826PubMedCrossRefGoogle Scholar
  9. 9.
    Ramnath N, Kim S, Christensen PJ (2011) Vitamin D and lung cancer. Expert Rev Respir Med 5:305–309PubMedCrossRefGoogle Scholar
  10. 10.
    Haussler MR, Haussler CA, Jurutka PW, et al. (1997) The vitamin D hormone and its nuclear receptor: molecular actions and disease states. The Journal of Endocrinology. 154 (Suppl): S57-73–S57-73Google Scholar
  11. 11.
    Zou A, Elgort MG, Allegretto EA (1997) Retinoid X receptor (RXR) ligands activate the human 25-hydroxyvitamin D3–24-hydroxylase promoter via RXR heterodimer binding to two vitamin D-responsive elements and elicit additive effects with 1,25-dihydroxyvitamin D3. J Biol Chem 272:19027–19034PubMedCrossRefGoogle Scholar
  12. 12.
    Arnhold T, Tzimas G, Wittfoht W, Plonait S, Nau H. (1996) Identification of 9-cis-retinoic acid, 9,13-di-cis-retinoic acid, and 14-hydroxy-4,14-retro-retinol in human plasma after liver consumption. Life Sci 59: PL169–77Google Scholar
  13. 13.
    Oh K, Willett WC, Wu K, Fuchs CS, Giovannucci EL (2007) Calcium and vitamin D intakes in relation to risk of distal colorectal adenoma in women. Am J Epidemiol 165:1178–1186PubMedCrossRefGoogle Scholar
  14. 14.
    Bao Y, Ng K, Wolpin BM, Michaud DS, Giovannucci E, Fuchs CS (2010) Predicted vitamin D status and pancreatic cancer risk in two prospective cohort studies. Br J Cancer 102:1422–1427PubMedCrossRefGoogle Scholar
  15. 15.
    Weinstein SJ, Yu K, Horst RL, Parisi D, Virtamo J, Albanes D (2011) Serum 25-hydroxyvitamin d and risk of lung cancer in male smokers: a nested case-control study. PLoS One 6:e20796PubMedCrossRefGoogle Scholar
  16. 16.
    Freedman DM, Looker AC, Abnet CC, Linet MS, Graubard BI (2010) Serum vitamin D and cancer mortality in the NHANES III study (1988–2006). Cancer Res 70:8587–8597PubMedCrossRefGoogle Scholar
  17. 17.
    Freedman DM, Looker AC, Chang S-C, Graubard BI (2007) Prospective study of serum vitamin D and cancer mortality in the United States. J Natl Cancer Inst 99:1594–1602PubMedCrossRefGoogle Scholar
  18. 18.
    Kilkkinen A, Knekt P, Heliövaara M et al (2008) Vitamin D status and the risk of lung cancer: a cohort study in Finland. Cancer Epidemiol Biomarkers Prev 17:3274–3278PubMedCrossRefGoogle Scholar
  19. 19.
    Giovannucci E, Liu Y, Rimm EB et al (2006) Prospective study of predictors of vitamin D status and cancer incidence and mortality in men. J Natl Cancer Inst 98:451–459PubMedCrossRefGoogle Scholar
  20. 20.
    Willett W (1998) Nutritional epidemiology, 2nd edn. Oxford University Press, OxfordCrossRefGoogle Scholar
  21. 21.
    Mannino DM, Gagnon RC, Petty TL, Lydick E (2000) Obstructive lung disease and low lung function in adults in the United States: data from the national health and nutrition examination survey, 1988–1994. Arch Intern Med 160:1683–1689PubMedCrossRefGoogle Scholar
  22. 22.
    Looker AC, Dawson-Hughes B, Calvo MS, Gunter EW, Sahyoun NR (2002) Serum 25-hydroxyvitamin D status of adolescents and adults in two seasonal subpopulations from NHANES III. Bone 30:771–777PubMedCrossRefGoogle Scholar
  23. 23.
    Gunter EW, Lewis BG, Koncikowski SM (1996) Laboratory procedures used for the Third National Health and Nutrition Examination Survey (NHANES III), 1988–1994Google Scholar
  24. 24.
    Cheung YB (2007) A modified least-squares regression approach to the estimation of risk difference. Am J Epidemiol 166:1337–1344PubMedCrossRefGoogle Scholar
  25. 25.
    Knoke JD, Burns DM, Thun MJ (2008) The change in excess risk of lung cancer attributable to smoking following smoking cessation: an examination of different analytic approaches using CPS-I data. Cancer Causes Control 19:207–219PubMedCrossRefGoogle Scholar
  26. 26.
    Ebbert JO, Yang P, Vachon CM et al (2003) Lung cancer risk reduction after smoking cessation: observations from a prospective cohort of women. J Clin Oncol 21:921–926PubMedCrossRefGoogle Scholar
  27. 27.
    Tong L, Spitz MR, Fueger JJ, Amos CA (1996) Lung carcinoma in former smokers. Cancer 78:1004–1010PubMedCrossRefGoogle Scholar
  28. 28.
    Ballew C, Galuska D, Gillespie C (2001) High serum retinyl esters are not associated with reduced bone mineral density in the third national health and nutrition examination survey, 1988–1994. J Bone Miner Res 16:2306–2312PubMedCrossRefGoogle Scholar
  29. 29.
    IOM (Institute of Medicine) (2011) Overview of Vitamin D. Dietary Reference Intake for Calcium and Vitamin D. Washington, DC: The National Academics PressGoogle Scholar
  30. 30.
    Park YK, Kim I, Yetley EA (1991) Characteristics of vitamin and mineral supplement products in the United States. Am J Clin Nutr 54:750–759PubMedGoogle Scholar
  31. 31.
    Bailey RL, Gahche JJ, Lentino CV et al (2011) Dietary supplement use in the United States, 2003–2006. J Nutr 141:261–266PubMedCrossRefGoogle Scholar
  32. 32.
    Higashimoto Y, Ohata M, Nishio K et al (1996) 1 alpha, 25-dihydroxyvitamin D3 and all-trans-retinoic acid inhibit the growth of a lung cancer cell line. Anticancer Res 16:2653–2659PubMedGoogle Scholar
  33. 33.
    Hershberger PA, Modzelewski RA, Shurin ZR, Rueger RM, Trump DL, Johnson CS (1999) 1,25-Dihydroxycholecalciferol (1,25–D3) inhibits the growth of squamous cell carcinoma and down-modulates p21(Waf1/Cip1) in vitro and in vivo. Cancer Res 59:2644–2649PubMedGoogle Scholar
  34. 34.
    Light BW, Yu WD, McElwain MC, Russell DM, Trump DL, Johnson CS (1997) Potentiation of cisplatin antitumor activity using a vitamin D analogue in a murine squamous cell carcinoma model system. Cancer Res 57:3759–3764PubMedGoogle Scholar
  35. 35.
    Nakagawa K, Sasaki Y, Kato S, Kubodera N, Okano T (2005) 22-Oxa-1alpha,25-dihydroxyvitamin D3 inhibits metastasis and angiogenesis in lung cancer. Carcinogenesis 26:1044–1054PubMedCrossRefGoogle Scholar
  36. 36.
    Mantell DJ, Owens PE, Bundred NJ, Mawer EB, Canfield AE (2000) 1 Alpha,25-dihydroxyvitamin D(3) inhibits angiogenesis in vitro and in vivo. Circ Res 87:214–220PubMedCrossRefGoogle Scholar
  37. 37.
    Bao BY, Yao J, Lee YF (2006) 1 Alpha, 25-dihydroxyvitamin D3 suppresses interleukin-8-mediated prostate cancer cell angiogenesis. Carcinogenesis 27:1883–1893PubMedCrossRefGoogle Scholar
  38. 38.
    Herbst RS, Heymach JV, Lippman SM (2008) Lung cancer. N Engl J Med 359:1367–1380PubMedCrossRefGoogle Scholar
  39. 39.
    Zhou W, Suk R, Liu G et al (2005) Vitamin D is associated with improved survival in early-stage non-small cell lung cancer patients. Cancer Epidemiol Biomarkers Prev 14:2303–2309PubMedCrossRefGoogle Scholar
  40. 40.
    Millen AE, Bodnar LM (2008) Vitamin D assessment in population-based studies: a review of the issues. Am J Clin Nutr 87:1102S–1105SPubMedGoogle Scholar
  41. 41.
    Hofmann JN, Yu K, Horst RL, Hayes RB, Purdue MP (2010) Long-term variation in serum 25-hydroxyvitamin D concentration among participants in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Epidemiol Biomarkers Prev 19:927–931PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2012

Authors and Affiliations

  • Ting-Yuan David Cheng
    • 1
    • 2
    Email author
  • Marian L. Neuhouser
    • 1
    • 2
  1. 1.Public Health Sciences DivisionFred Hutchinson Cancer Research CenterSeattleUSA
  2. 2.Department of EpidemiologyUniversity of WashingtonSeattleUSA

Personalised recommendations